Evidence level: B
上一篇的结论是:用”当下的 25(OH)D 血清值”给太阳暴露分层是错的,因为这个分层变量自己会随暴露移动,建议换一个暴露窗口内相对固定的变量——并点名了 GC 基因型。这一篇来验收这个候选。它确实不会动,但它动的是别的东西。
正文
上一篇(太阳周期×基线维生素D 交互项)的结论是:基线 25(OH)D 这个修饰变量有三个身份——被测错、随暴露移动、被疾病反向压低。出路是换一个在暴露窗口内相对固定的分层变量,并点名了 GC rs4588。
结论先说:它不会动,但它动的是车,不是货。
一、它动的是车,不是货
rs4588 是 GC 基因上的错义突变,编码维生素D结合蛋白(DBP)——把 25(OH)D 从肝脏运到全身的那辆车。A 等位把第 436 位苏氨酸换成赖氨酸,得到 Gc2 型蛋白,结合亲和力更低(PMID 24472850)。
Powe 2013 在 2,085 名黑人与白人中发现:GC 多态性单独解释了 79.4% 的 DBP 水平变异,却只解释了 9.9% 的总 25(OH)D 变异(PMID 24256378)。这个基因主要决定车有多少,顺带把货的账面数拉低了一点。
而账面数(总 25(OH)D)不等于实际到货(游离 25(OH)D)。用 rs4588 当”缺乏倾向”的工具变量,测到的主要是载体蛋白浓度倾向,不是细胞可用维生素D的缺乏倾向——基因型经”运输”这条绕过”功能性缺乏”的路直接够到结局,违反排除限制假设。
二、换一个仪器,符号会翻
Afzal 2014 在 95,766 名丹麦白人中做 MR,拆开看同一结局:CYP2R1 评分给出心血管死亡 OR 0.60(0.40-0.91,保护方向),DHCR7 评分给出 OR 1.13(0.63-2.03,相反方向)(PMID 25406188)。同一批人、同一暴露、同一结局,只换仪器,符号就翻了。Berry 2012 早写下判据:若 DHCR7 上的关联在 CYP2R1 上没有,就要怀疑多效性(PMID 22629401)。
三、「缺乏倾向」不是一个恒定属性
Martineau 2009:古吉拉特裔中 Gc2/2 相比 Gc1/1,活动性结核 OR 2.81(1.19-6.66,P=0.009);但该关联只在血清 25(OH)D <20 nmol/L 时保留(P=0.01),≥20 nmol/L 时完全消失(P=0.36),且在巴西成人、南非儿童两个队列里毫无关联(PMID 19797128)。
结构很关键:基因型不单独产生风险,基因型与环境水位相乘才产生风险。 它不是一张固定的牌,是一个只在低水位时才打开的阀门。
四、单 SNP 不是单倍型
GC 的三个主要异构体由 rs4588 与 rs7041 的组合决定:Gc1F = rs7041-T + rs4588-C,Gc1S = rs7041-G + rs4588-C,Gc2 = rs7041-T + rs4588-A。
2026 年一篇纳入 30 项研究、8,844 人的 meta 分析给出干净对照:rs7041 与 rs4588 这两个单点,与 COPD 易感性都不显著(P 均 >0.05);但按双倍型分组后,GC1F/1F 对 GC1S/1S 的 OR 达 2.17,等位基因分析 P=0.0003;且只在东亚人群显著(DOI 10.1186/s12920-026-02443-1)。早前两篇 meta 结构相同:GC1F 增风险、GC1S/GC2 保护,只在亚洲人显著(PMID 26380769、PMID 31156695)。中国汉族人群中 Gc2 与哮喘的 OR 为 1.35(PMID 21810276)——同一个基因型在不同疾病、不同族群上给出不同方向的答案。
五、尺子本身也有偏
Nielson 2016 用三种方法测同一批人的 DBP:单克隆抗体法测出非洲裔比白人低约 50%,多克隆抗体法与蛋白质组学法没有差异(PMID 27007693)。Powe 那个”黑白生物可利用 25(OH)D 相同”的著名结论,很大部分来自单抗对 GC1F 异构体的识别偏倚。
基因型既改变了被测物(总 25(OH)D),也改变了尺子(不同异构体与抗体的结合效率)。 一个变量同时出现在方程两边。
六、GWAS 已经把这个明星降级了
Manousaki 2020 用 401,460 名英国白人加 42,274 名欧洲人的 GWAS,识别出 138 个条件独立 SNP、映射到 69 个位点,遗传力 16.1%,且与部分社会经济性状共享遗传力,可能经”户外时间”中介(PMID 32059762)。当仪器从 1 个 SNP 扩到 138 个,评分测的已经是”户外时间+肝脏代谢+社会经济”的混合体。而非裔人群 GWAS 里,rs4588 是唯一与 25(OH)D 全基因组显著相关的位点,rs7041 则主要与 DBP 浓度相关(PMID 36811574)——同一个基因,两个位点,管两件事。
七、反方压力(必须摆上桌)
支持”能用”的证据不是没有。Çolak 2021 在 116,335 名丹麦白人中:遗传预测 25(OH)D 每低 10 nmol/L,细菌性肺炎 OR 1.12(1.02-1.23);但 MR-Egger 给出 1.63(0.96-2.78,不显著),且作者指出关联最强的变异在 CYP2R1 附近,不是 GC(PMID 33109689)。
阴性侧更整齐。Butler-Laporte 2021 用 443,734 人的 25OHD GWAS 当工具,COVID-19 易感性 OR 0.95(0.84-1.08)、住院 1.09、重症 0.97,全阴(PMID 34061844)。但作者写了一句话,恰好就是本篇主题:“本结果不适用于已经缺乏维生素D的人”。Bouillon 2022 综述统计:60 多个维生素D MR 研究大多为阴,只有 4 个在多发性硬化上取得一致阳性(PMID 34815552)。
全样本平均为零,推不出缺乏亚组也为零。 MR 的设计目标本就是估”平均因果效应”,从未被设计来估”效应修饰”。
八、真要做,该怎么做
STROBE-MR 要求报告三种核心假设、F 统计量/R²(判断弱工具偏倚)与敏感性分析(PMID 34698778);Burgess 2019 指南要求散点图/漏斗图看异质性并做三角互证(PMID 32760811)。至少要做到:
- 双轨并行:一路用基因型分层(固定,但测的是载体蛋白),一路用直接测量的游离 25(OH)D 分层(测功能,但会随暴露移动),看两条路是否同向;
- 按功能分组仪器:合成通路(DHCR7/CYP2R1)与运输/代谢通路(GC/CYP24A1)分开评分,方向不一致就按 Berry 判据处理为多效性信号;用双倍型而非单点;
- 事前指定低水位窗口:Martineau 说效应只在 <20 nmol/L 存在,就必须事前指定,不是事后翻数据找显著区间。
功效门槛也需记住:Berry 的算例是 80% 功效约需 8 万人。交互项样本量远低于此,阴性结果应读作”未检验”而非”已否定”。
九、易学落点
传统术数里,”先天禀赋”(命局、胎元、根基)常被当作与时间无关的固定属性:命里不足就是不足,走到哪里都不足。本篇的证据说,所谓”先天不足倾向”更像一个阈值触发器——Gc2/2 只在血清 25(OH)D 低于 20 nmol/L 时才与结核风险相关,水位一升上去,基因型就沉默了。
若把”根基浅”当固定牌,人只能被动接受;若把它当阀门,问题就变成”把水位维持在阈值以上”——而水位可以靠晒、靠食、靠时令调。本篇的分辨点是:先天因素不决定结局,它决定”在什么水位下显形”。
证据与局限
已验证: GC 多态性是 DBP 浓度的主要决定因素(解释 79.4% 变异),对总 25(OH)D 解释力小得多(9.9%);rs4588 的 A 等位降低 DBP 与总 25(OH)D;不同 GC 异构体结合亲和力有实测差异;Gc2/2 与结核风险的关联只在 25(OH)D <20 nmol/L 时出现;rs7041/rs4588 单点与 COPD 不显著而 GC 双倍型显著。
部分验证: 遗传预测的低 25(OH)D 与细菌性肺炎风险的关联(阳性,但最强信号在 CYP2R1 而非 GC,MR-Egger 不显著);GC 变异与哮喘/COPD 的族群特异性关联(东亚显著、非东亚多为阴性);遗传低 25(OH)D 与多发性硬化的关联(4 个 MR 一致阳性,是少数例外领域)。
待验证: ①GC 基因型作为分层变量时,缺乏亚组中”太阳周期-呼吸道感染”关联强度是否显著高于充足亚组(从未直接检验);②游离 25(OH)D 分层与总 25(OH)D 分层在交互项上是否给出一致结论;③基因型驱动的是否主要是载体蛋白通路而非功能缺乏通路(需在分层设计中加测 DBP 与直接法游离 25(OH)D 做中介分解)。
可证伪预测: 若 GC 基因型真是干净的”缺乏倾向”仪器,则①控制直接测量的游离 25(OH)D 后,基因型与感染结局的关联应大幅衰减;②合成通路与运输通路两组仪器应给出同向估计;③双倍型分层应比单点分层显示更强的交互信号。三点都不成立 → GC 基因型不能承担这个角色,需要换的是暴露定义,不是仪器。
相关阅读
- 缺D的人受太阳影响更大吗?「太阳周期×基线维生素D」交互项检验的三重身份陷阱
- 基线维生素D状态的效应修饰:为什么”补同样的量”效果差很多
- 紫外线通路中”依赖维生素D”与”非依赖维生素D”两条路的分离
- 维生素D是太阳周期与健康之间的中介变量吗?
- 环境-生命频率接口(研究池4)
证据等级: B
参考文献: PMID 24256378, PMID 27007693, PMID 26733479, PMID 25406188, PMID 19797128, PMID 31156695, PMID 26380769, PMID 21810276, PMID 32059762, PMID 22629401, PMID 33109689, PMID 34061844, PMID 34815552, PMID 34698778, PMID 32760811, PMID 36811574, PMID 38644690, PMID 24472850, PMID 34675344;另引 DOI 10.1186/s12920-026-02443-1
免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。
Can GC Genotype Serve as an Instrumental Variable for \”Propensity to Lack\”? It Moves the Car, Not the Cargo
Evidence level: B
The previous conclusion was that using “current 25(OH)D serum levels” for stratification by solar exposure is incorrect because this stratification variable itself moves with the exposure. A relatively fixed variable within the exposure window should be used instead, and GC genotype was specifically named. This article validates that candidate. It indeed does not move, but it moves the car, not the cargo.
Main Text
The conclusion from the previous article (Solar Cycle × Baseline Vitamin D interaction term) is that the baseline 25(OH)D modifier variable has three identities: mis-measured, moving with exposure, and downwardly biased by disease. The solution is to switch to a stratification variable that is relatively fixed within the exposure window, specifically naming GC rs4588.
Conclusion first: It does not move, but it moves the car, not the cargo.
I. It Moves the Car, Not the Cargo
rs4588 is a missense mutation on the GC gene encoding Vitamin D Binding Protein (DBP)—the vehicle that transports 25(OH)D from the liver to the rest of the body. The A allele substitutes Threonine at position 436 with Lysine, resulting in the Gc2 protein type with lower binding affinity (PMID 24472850).
Powe et al. (2013) found in 2,085 Black and White individuals that GC polymorphism alone explained 79.4% of DBP level variation but only 9.9% of total 25(OH)D variation (PMID 24256378). This gene primarily determines how many vehicles there are, while also slightly lowering the ledger count of the cargo.
However, the ledger count (total 25(OH)D) is not equal to actual delivery (free 25(OH)D). Using rs4588 as an instrumental variable for “deficiency propensity” measures primarily carrier protein concentration tendency, not cellular vitamin D deficiency tendency. The genotype bypasses the “functional deficiency” pathway via the “transportation” route to reach the outcome, violating the exclusion restriction assumption.
II. Change the Instrument, and the Sign Flips
Afzal et al. (2014) conducted a Mendelian Randomization (MR) study in 95,766 Danish whites, examining the same outcome separately: CYP2R1 scoring yielded a cardiovascular death OR of 0.60 (0.40-0.91, protective direction), while DHCR7 scoring yielded an OR of 1.13 (0.63-2.03, opposite direction) (PMID 25406188). Same population, same exposure, same outcome; simply changing the instrument flipped the sign. Berry et al. (2012) established the criterion early on: if the association on DHCR7 is absent on CYP2R1, one should suspect pleiotropy (PMID 22629401).
III. “Deficiency Propensity” Is Not a Constant Attribute
Martineau et al. (2009): Among Gujarati descendants, Gc2/2 compared to Gc1/1 showed an activity-associated tuberculosis OR of 2.81 (1.19-6.66, P=0.009); however, this association was retained only when serum 25(OH)D <20 nmol/L (P=0.01), completely disappearing at ≥20 nmol/L (P=0.36), and showed no association in two cohorts of Brazilian adults and South African children (PMID 19797128).
Structure is critical: Genotype does not independently generate risk; genotype interacts with environmental water levels to produce risk. It is not a fixed card, but a valve that opens only at low water levels.
IV. Single SNP Is Not a Haplotype
The three main GC isoforms are determined by the combination of rs4588 and rs7041: Gc1F = rs7041-T + rs4588-C, Gc1S = rs7041-G + rs4588-C, Gc2 = rs7041-T + rs4588-A.
A 2026 meta-analysis including 30 studies and 8,844 individuals provided a clean control: Neither single point rs7041 nor rs4588 showed significant association with COPD susceptibility (P >0.05 for both); however, after grouping by haplotype doublets, the OR for GC1F/1F vs. GC1S/1S reached 2.17, with allele analysis P=0.0003; and significance was observed only in East Asian populations (DOI 10.1186/s12920-026-02443-1). Earlier two meta-analyses with similar structures showed GC1F increased risk while GC1S/GC2 were protective, significant only in Asians (PMID 26380769, PMID 31156695). In Chinese Han populations, Gc2 had an OR of 1.35 for asthma (PMID 21810276)—the same genotype yields different directional answers across different diseases and populations.
V. The Ruler Itself Is Biased
Nielson et al. (2016) measured DBP in the same cohort using three methods: monoclonal antibody assay showed African Americans were ~50% lower than Whites; polyclonal antibody and proteomics methods showed no difference (PMID 27007693). A large part of Powe’s famous conclusion that “Black and White biological availability of 25(OH)D is the same” stems from monoclonal antibody bias against the Gc1F isoform.
Genotype alters both the measured substance (total 25(OH)D) and the ruler (binding efficiency of different isoforms with antibodies). A variable appears on both sides of the equation.
VI. GWAS Has Downgraded This Star
Manousaki et al. (2020) used a GWAS with 401,460 British whites and 42,274 Europeans to identify 138 conditionally independent SNPs mapped to 69 loci, with heritability of 16.1%, and shared genetic liability with some socioeconomic traits, potentially mediated by “outdoor time” (PMID 32059762). When the instrument expands from 1 SNP to 138, the score measures a mixture of “outdoor time + liver metabolism + socioeconomic factors.” In African American GWAS, rs4588 was the only locus genome-wide significant for 25(OH)D, while rs7041 was primarily associated with DBP concentration (PMID 36811574)—the same gene, two loci, managing two different things.
VII. Counter-Argument Pressure (Must Be Placed on the Table)
Evidence supporting “it can be used” is not absent. Çolak et al. (2021) in 116,335 Danish whites: genetic prediction showed that for every 10 nmol/L lower 25(OH)D, bacterial pneumonia OR was 1.12 (1.02-1.23); however, MR-Egger gave 1.63 (0.96-2.78, not significant), and the authors noted the strongest associated variant was near CYP2R1, not GC (PMID 33109689).
Negative results are more consistent. Butler-Laporte et al. (2021) used the 25OHD GWAS of 443,734 people as an instrument; COVID-19 susceptibility OR was 0.95 (0.84-1.08), hospitalization 1.09, severity 0.97—all negative (PMID 34061844). However, the authors wrote a sentence that coincidentally matches this article’s theme: “These results do not apply to individuals who are already vitamin D deficient.” Bouillon et al. (2022) review statistics: most of over 60 vitamin D MR studies are negative, with only 4 showing consistent positive results in multiple sclerosis (PMID 34815552).
Zero average across the whole sample does not imply zero in the deficiency subgroup. MR design aims to estimate “average causal effect” and was never designed to estimate “effect modification.”
VIII. If You Must Do It, How Should You Do It
STROBE-MR requires reporting three core assumptions, F-statistics/R² (to judge weak instrument bias), and sensitivity analyses (PMID 34698778); Burgess et al. (2019) guidelines require scatter plots/histograms to check heterogeneity and triangulation (PMID 32760811). At minimum, achieve:
- Dual-track parallelism: One track uses genotype stratification (fixed, but measures carrier protein); the other uses directly measured free 25(OH)D stratification (measures function, but moves with exposure), to see if both tracks align;
- Group instruments by function: Separate scoring for synthetic pathways (DHCR7/CYP2R1) and transport/metabolic pathways (GC/CYP24A1); if directions are inconsistent, treat as pleiotropy signals per Berry’s criterion; use doublets rather than single points;
- Pre-specify low-water-level windows: Martineau stated the effect exists only below 20 nmol/L; it must be pre-specified, not found post-hoc by searching for significant intervals.
Also remember the power threshold: Berry’s calculation suggests ~80% power requires 80,000 people. Interaction study sample sizes are far below this; negative results should be read as “not tested” rather than “negated.”
IX. Yijing Application Point
In traditional numerology, “innate endowment” (destiny chart, fetal element, foundation) is often treated as a fixed attribute unrelated to time: if insufficient in the destiny, it remains insufficient regardless of location. This article’s evidence suggests that so-called “innate deficiency tendency” is more like a threshold trigger—Gc2/2 is only associated with tuberculosis risk when serum 25(OH)D is below 20 nmol/L; once water levels rise, the genotype goes silent.
If “shallow foundation” is treated as a fixed card, one can only passively accept it; if treated as a valve, the problem becomes “maintaining water levels above the threshold”—which can be adjusted via sun exposure, diet, or seasonal timing. The distinguishing point of this article is: Innate factors do not determine the outcome; they determine “at what water level the manifestation occurs.”
Evidence and Limitations
Verified: GC polymorphism is the primary determinant of DBP concentration (explaining 79.4% variation), with much weaker explanatory power for total 25(OH)D (9.9%); A allele of rs4588 lowers DBP and total 25(OH)D; different GC isoforms have measured differences in binding affinity; Gc2/2 association with tuberculosis risk appears only when 25(OH)D <20 nmol/L; single points rs7041/rs4588 are not significant for COPD while GC doublets are.
Partially Verified: Association between genetically predicted lower 25(OH)D and bacterial pneumonia risk (positive, but strongest signal near CYP2R1 not GC, MR-Egger not significant); population-specific associations between GC variants and asthma/COPD (significant in East Asia, mostly negative elsewhere); association between genetically lower 25(OH)D and multiple sclerosis (4 MR studies consistent positive, a minority exception field).
To Be Verified: ① When GC genotype is used as a stratification variable, is the “Solar Cycle × Respiratory Infection” association strength in the deficiency subgroup significantly higher than in the sufficient subgroup (never directly tested); ② Whether free 25(OH)D stratification and total 25(OH)D stratification yield consistent conclusions in interaction terms; ③ Whether genotype drives primarily the carrier protein pathway rather than functional deficiency pathway (requires adding DBP measurement and direct free 25(OH)D in stratified design for mediation decomposition).
Falsifiable Predictions: If GC genotype is truly a clean “deficiency propensity” instrument, then ① controlling for directly measured free 25(OH)D should cause a substantial attenuation of the genotype-outcome association; ② synthetic and transport pathway instrument groups should yield consistent estimates; ③ doublet stratification should show stronger interaction signals than single-point stratification. If none of these hold → GC genotype cannot bear this role; the exposure definition needs changing, not the instrument.
Related Reading
- Do people lacking D suffer more from the Sun? ‘Solar Cycle × Baseline Vitamin D’ Interaction Effect Modification Triple Identity Trap
- Effect Modification of Baseline Vitamin D Status: Why ‘Same Amount Supplementation’ Yields Very Different Results
- Separation of ‘Vitamin D Dependent’ and ‘Non-Vitamin D Dependent’ Paths in UV Pathway
- Is Vitamin D a Mediator Variable Between Solar Cycle and Health?
- Environment-Life Frequency Interface (Research Pool 4)
Evidence Level: B
References: PMID 24256378, PMID 27007693, PMID 26733479, PMID 25406188, PMID 19797128, PMID 31156695, PMID 26380769, PMID 21810276, PMID 32059762, PMID 22629401, PMID 33109689, PMID 34061844, PMID 34815552, PMID 34698778, PMID 32760811, PMID 36811574, PMID 38644690, PMID 24472850, PMID 34675344; also cited DOI 10.1186/s12920-026-02443-1
Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.
Leave a Reply